Company intelligence / Profile preview

Tobira Therapeutics

South San Francisco, California, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Tobira Therapeutics was a clinical-stage biopharmaceutical company developing therapies for liver diseases and inflammation. Its lead candidate, cenicriviroc—a dual CCR2/CCR5 inhibitor—was in Phase 2b trials for NASH and liver fibrosis. The company also investigated CVC for primary sclerosing cholangitis and HIV. Another pipeline asset was evogliptin, a DPP4 inhibitor intended for combination therapy in NASH. In September 2016, Allergan acquired Tobira to strengthen its portfolio in gastroenterology R&D with a focus on NASH treatments.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Small molecules (e.g., cenicriviroc, evogliptin)
Industry: Biotech

Drug pipeline

1 asset

cenicriviroc

Phase 2

Indications: NASH, HIV-1

Partnerships

Strategic partnerships planned or ongoing for HIV program development; specifics not detailed

Beyond the preview

Go deeper on Tobira Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tobira Therapeutics.

Explore the full profile